UVEITIS TREATED WITH DEXAMETHASONE IMPLANT.
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
01 Mar 2021
01 Mar 2021
Historique:
pubmed:
4
7
2020
medline:
17
11
2021
entrez:
4
7
2020
Statut:
ppublish
Résumé
To evaluate the real-life efficacy and safety of the intravitreal dexamethasone implant in uveitis. This retrospective observational multicentric study included 152 eyes treated exclusively by 358 dexamethasone implant injections. The main outcome measures included change in the best-corrected visual acuity, central macular thickness, and vitreous haze score. Patients were treated with dexamethasone implant for macular edema (51.3%), vitritis with macular edema (40.1%), vitritis (5.3%), and other causes (3.3%). The mean duration of follow-up was 19.0 months. The mean gain in best-corrected visual acuity during follow-up was +12.1 letters. An improvement in best-corrected visual acuity ≥5, 10, and 15 letters was found in 64.5, 50.7, and 35.5% of cases, respectively. 59.7% of eyes with macular edema at baseline were found to be anatomical responders. Vitritis resolution (vitreous haze = 0+) was obtained in 81.4% of cases. Ocular hypertension (intraocular pressure ≥25 mmHg and/or gain ≥10 mmHg from baseline) occurred in 28.3% of patients. No filtering surgery/laser therapy was required. A total of 40.2% of phakic subjects underwent cataract surgery on average 11.2 months after the first injection. This study confirms the efficacy and safety of the dexamethasone implant in noninfectious uveitis. Cataract and ocular hypertension were not uncommon but easily manageable.
Identifiants
pubmed: 32618834
pii: 00006982-202103000-00023
doi: 10.1097/IAE.0000000000002901
doi:
Substances chimiques
Drug Implants
0
Glucocorticoids
0
Dexamethasone
7S5I7G3JQL
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
620-629Déclaration de conflit d'intérêts
T. Mathis declared conflicts of interest from Allergan, Bayer, and Novartis; M. Weber declared conflicts of interest from Allergan; P. Denis declared conflicts of interest from Allergan and Novartis; B. Bodaghi declared conflicts of interest from AbbVie, Allergan, Alimera, and Santen; L. Kodjikian declared conflicts of interest from AbbVie, Allergan, Bayer, Novartis, Roche, and Théa. None of the other authors has any financial interests to disclose.
Références
Bodaghi B, Cassoux N, Wechsler B, et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore) 2001;80:263–270.
de Smet MD, Taylor SRJ, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011;30:452–470.
Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Kempen JH, Altaweel MM, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 2011;118:1916–1926.
Lowder C, Belfort R, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545–553.
Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol 2007;125:1478–1485.
Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138:740–743.
Pohlmann D, Vom Brocke GA, Winterhalter S, et al. Dexamethasone inserts in noninfectious uveitis: a single-center experience. Ophthalmology 2018;125:1088–1099.
Zarranz-Ventura J, Carreño E, Johnston RL, et al. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol 2014;158:1136–1145.e5.
Tomkins-Netzer O, Taylor SRJ, Bar A, et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology 2014;121:1649–1654.
Khurana RN, Bansal AS, Chang LK, et al. Prospective evaluation of a sustained-release dexamethasone intravitreal implant for cystoid macular edema in quiescent uveitis. Retina 2017;37:1692–1699.
Breitbach M, Rack D, Dietzel M, et al. Efficacy of a dexamethasone implant for the treatment of refractory cystoid macular oedema in non-infectious uveitis [in German]. Klin Monbl Augenheilkd 2016;233:601–605.
Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009;147:1048–1052.
Habot-Wilner Z, Sorkin N, Goldenberg D, et al. Long-term outcome of an intravitreal dexamethasone implant for the treatment of noninfectious uveitic macular edema. Ophthalmologica 2014;232:77–82.
Khurana RN, Porco TC. Efficacy and safety of dexamethasone intravitreal implant for persistent uveitic cystoid macular edema. Retina 2015;35:1640–1646.
Gilbert EH, Lowenstein SR, Koziol-McLain J, et al. Chart reviews in emergency medicine research: where are the methods? Ann Emerg Med 1996;27:305–308.
Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 2005;140:509–516.
Singer MA, Dugel PU, Fine HF, et al. Real-world assessment of dexamethasone intravitreal implant in DME: findings of the prospective, multicenter REINFORCE study. Ophthalmic Surg Lasers Imaging Retina 2018;49:425–435.
Kodjikian L, Bellocq D, Mathis T. Pharmacological management of diabetic macular edema in real-life observational studies. Biomed Res Int 2018;2018:16.
Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol 1963;70:500–507.
Diggle P, Heagerty P, Liang KY, Zeger S. Analysis of Longitudinal Data. 2nd ed. Boca Raton, FL: CRC Press; 2002.
Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963–974.
Thorne JE, Sugar EA, Holbrook JT, et al. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) trial. Ophthalmology 2019;126:283–295.
Pelegrín L, de la Maza MS, Molins B, et al. Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis. Eye (Lond) 2015;29:943–950.
Malclès A, Dot C, Voirin N, et al. Safety of intravitreal dexamethasone implant (Ozurdex): the SAFODEX study. Incidence and risk factors of ocular hypertension. Retina 2017;37:1352–1359.
Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol 2011;129:914–920.
Tufail A, Lightman S, Kamal A, et al. Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis. Clin Ophthalmol 2018;12:2519–2534.
Malclès A, Dot C, Voirin N, et al. Real-life study in diabetic macular edema treated with dexamethasone implant: the reldex study. Retina 2017;37:753–760.
Saturni S, Bellini F, Braido F, et al. Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view. Pulm Pharmacol Ther 2014;27:129–138.
Herland K, Akselsen JP, Skjønsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med 2005;99:11–19.
Tsang AC, Virgili G, Abtahi M, Gottlieb CC. Intravitreal dexamethasone implant for the treatment of macular edema in chronic non-infectious uveitis. Ocul Immunol Inflamm 2017;25:685–692.